Drug Profile
Perflenapent - NuvOX Pharma
Alternative Names: DDFPe; Dodecafluoropentane; NanO2; NVX 208; NVX-108; Perfluoropentane; PFPLatest Information Update: 07 Apr 2023
Price :
$50
*
At a glance
- Originator NuvOx Pharma
- Class Anti-ischaemics; Antianaemics; Antihaemorrhagics; Antineoplastics; Fluorocarbons; Neuroprotectants; Radiation-sensitising agents; Radiosensitisers; Small molecules; Vascular disorder therapies
- Mechanism of Action Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma; Stroke
- Preclinical Haemorrhagic shock; Myocardial infarction; SARS-CoV-2 acute respiratory disease; Sickle cell anaemia; Traumatic brain injuries; Triple negative breast cancer
Most Recent Events
- 31 Mar 2023 Phase-II clinical trials in Glioblastoma (Newly diagnosed, Combination therapy, First-line therapy) in USA (IV) (NCT03862430)
- 02 Mar 2023 NuvOx Pharma has patent protection for Perflenapent in USA
- 02 Mar 2023 Adverse events and pharmacodynamics data from preclinical studies in Stroke released by NuvOx Pharma